Download Boston 2017b – Onsite Agenda - Immune Checkpoint Inhibitors

Conference Day 1 – Wednesday, March 15
08.15 Chair’s Opening Remarks
Capitalize On Future Immuno-Oncology Opportunities
08.30 Evaluating The Role Of Precision Medicine In Immuno-Oncology
David Kaufman, Executive Director, Translational Immuno- Oncology, Merck
09.00 Case Study: Comprehensive Insights Into The Atezolizumab Combination Strategy Across Various
Tumor Types
Xiaosong Zhang, Assistant Medical Director, Genentech
09.30 Speed Networking & Morning Refreshments
PRECLINICAL STREAM: Validate Translational
Biomarkers To Select Patients Effectively
11.00 A Multianalyte Algorithmic Analysis To Predicting
Response To Checkpoint Inhibitors
Carl Morrison, President, CSO and Founder, OmniSeq
CLINICAL STREAM: Enhance Combination Strategies
To Maximize Efficacy
11.00 What Are The Key Issues In The Design Of
Combination Checkpoint Inhibitor Trials?
Michael Postow, Medical Oncologist, Melanoma &
Immunotherapeutics Service, MSKCC
11.30 Biomarker-Driven Indication And Patient
Selection In The ICONIC Trial
Beth Trehu, CMO, Jounce Therapeutics
11.30 Investigating Novel Combination Strategies
Involving Immune Checkpoint Inhibitors And Targeted
Therapeutics
David Schaer, Principal Research Scientist, Cancer
Immunobiology, Eli Lilly
12.00 Achieving Objective Measurement And
Significance Of Novel Immunotherapy Targets In Human
Malignancies
Kurt Schalper, Assistant Professor of Pathology &
Medicine, Yale School of Medicine
12.00 Rationale For Combining Targeted And
Conventional Cancer Therapy With Immunotherapy
Phil Gotwals, Executive Director, Immuno-Oncology,
Novartis
12:30 A Fresh Approach To Immuno-Oncology: Ex Vivo
Analysis Of Drug Efficacy In Fresh Patient Tumor Tissue
Soner Altiok, CSO, Nilogen Oncosystems
12:30 Clinical Anti-Tumour Effects Observed with
LTX-315 Monotherapy; Combination With Immune
Checkpoints Ongoing
Øystein Rekdal, CSO, Lytix Biopharma
Andrew Saunders, CMO, Lytix Biopharma
1:00
Lunch & Networking
PRECLINICAL STREAM: Advancing Our Understanding Of
The Tumor Microenvironment
14.00 A Novel Phenotypic Platform for Predicting
Tumor Immune Response
Parker Cassidy, Chief Commercial Officer, Mitra Biotech
CLINICAL STREAM: Pioneering Novel Checkpoint
Modulators Through The Clinic
14.00 Key Considerations And Future Opportunities In
The Clinical Investigation Of Immuno-Oncology
Combinations
Jon Wigginton, CMO & SVP, Clinical Development,
MacroGenics
14.30 Microenvironmental Regulation Of Anti-Tumor
Immune Responses: A Lesson From Fibroblastic Cells
Viviana Cremasco, Investigator III, Novartis
14.30 Developing Orally Bioavailable Small Molecules
Targeting Single And Multiple Immune Inhibitory
Pathways As A Novel Immuno-Oncology Strategy
David Tuck, CMO, Curis
15.00 Targeting CD47 To Involve Macrophages And
Dendritic Cells In A Holistic Anti-Tumor Immune
Response
Marie Kosco-Vilbois, CSO, Novimmune
15.00 Two Active Immunotherapies In Melanoma
(TACTI-Mel Phase I Trial): Combination Of IMP321 (LAG3Ig) With An Anti-PD-1 Antagonist (Pembrolizumab) In
A Phase I Trial
Frédéric Triebel, CSO & CMO, Prima Biomed
15.30 Afternoon Refreshments & Networking
Improving Discovery, In Vivo Validation And Translatability Into The Clinic
16.00 Enabling Cancer Immunotherapy From Discovery To Combinations
Alison O’Mahony, Vice President of Research Biology (BioMAP), DiscoverX
16.30 The Functional Programs And Molecular Mechanisms That Optimize Cytotoxic T Cells (CTLs) For Their AntiTumor Efficacy
Jannie Borst, Head of Division, Immunology, Netherlands Cancer Institute
17.00 Enhancing The Translatability Of Preclinical Models To Boost Translation Into The Clinic
Andrew Zloza, Section Chief of Surgical Oncology Research,, Rutgers Cancer Institute of New Jersey
17.30 Chair’s Closing Remarks
Conference Day 2 – Thursday, March 16
08.45 Chair’s Opening Remarks
Strategic & Scientific Approaches To Pioneer Future Progress In Immuno-Oncology
09.00 The Science And Art Of Immuno-Oncology: Integrating IO Treatment Solutions Into Real-World Oncology
Practice
Zhen Su, VP, Head of Global Medical Affairs, Oncology, EMD Serono
09.30 Insights Into The Optimal Combination Strategies To Convert Cold To Hot Tumors
Prasad Adusumilli, Deputy Chief, Thoracic Service, MSKCC
10.00 Interactive Mastermind Session: How Can We Collectively Enhance IO Drug Development?
10.30 Morning Refreshments & Networking
PRECLINICAL STREAM: Validate Novel Checkpoints And
Preclinical Combinations
11:00 Utilizing Mouse Models to Better Understand the
Pathways and Mechanisms of Emerging Immune
Therapies
Rick Huntress, Director, Business Development, Clinical &
In Vivo Services, The Jackson Laboratory
CLINICAL STREAM: Investigate Clinical Strategies To
Enhance Efficacy And Reduce Adverse Events
11.00 Immune Checkpoint Therapy Toxicities – Lessons
Learned And New Strategies To Improve Outcomes
Geoff Gibney, Co-Leader, Melanoma Disease Group,
Lombardi Comprehensive Cancer Center
11.30 Preclinical Investigation Of The Promise And
Challenges Of Agonistic Anti-GITR Antibody Therapy
Amy Beebe, Senior Principal Scientist, Merck
11.30 Delivering On The Science – Early Development
Strategies For The Brave New World Of
Immunomodulators
Moitreyee Chatterjee-Kishore, Senior Director, ImmunoOncology, Janssen
12.00 Lunch & Networking
PRECLINICAL STREAM: Validate Novel Checkpoints And
Preclinical Combinations
13.30 Co-Inhibition Of CD73 And A2AR Adenosine
Signaling Improves Preclinical Anti-Tumor Immune
Responses
Kris Sachsenmeier, Associate Director, Translational
Science – Oncology, AstraZeneca
CLINICAL STREAM: Innovations To Enhance
Clinical Outcomes
13.30 Discovering Combination Strategies In Solid
Tumors Through Creative Trial Design With CAR T Cell
Therapy
Jennifer Brogdon, Director, Exploratory ImmunoOncology, Novartis
14.00 Preclinical Evaluation Of An Immune Checkpoint
Target And An Agonist GITR Ligand
Angie Park, Senior Director, Immunotherapy & Stem Cell
Biology, OncoMed
14.00 Molecular Features Within Tumors Associated
With Immunotherapy Efficacy
Scott Woodman, Assistant Professor, MD Anderson
Cancer Center
14.30 Afternoon Refreshments & Networking
Navigate The Rapidly Evolving IO Landscape To Ensure Future Success
15.00 Mechanisms Of Action Of Talimogene Laherparepvec: From Bench To Bedside
Pedro Beltran, Oncology Research, Executive Director, Amgen
15:30
Activation Of STING With Synthetic Cyclic Dinucleotides Synergizes With Checkpoint Inhibition To Induce
Anti- Tumor Immunity
Sarah McWhirter, Director, STING Program, Aduro BioTech
16:00 Panel Discussion: Cross-Industry Perspectives On The Future Of Immuno-Oncology
 How can past challenges, including setbacks in recent checkpoint modulator clinical progression, be
interrogated to develop successful future strategies
 What are the most immediate challenges that the field needs to prioritize?
 What does the next 5-10 years hold for this rapidly-evolving field?
16.45 Chair’s Closing Remarks